JP2023065516A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023065516A5 JP2023065516A5 JP2023026870A JP2023026870A JP2023065516A5 JP 2023065516 A5 JP2023065516 A5 JP 2023065516A5 JP 2023026870 A JP2023026870 A JP 2023026870A JP 2023026870 A JP2023026870 A JP 2023026870A JP 2023065516 A5 JP2023065516 A5 JP 2023065516A5
- Authority
- JP
- Japan
- Prior art keywords
- promoter
- nucleic acid
- acid molecule
- tuberin
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762507358P | 2017-05-17 | 2017-05-17 | |
| US62/507,358 | 2017-05-17 | ||
| JP2019558745A JP7235676B2 (ja) | 2017-05-17 | 2018-05-17 | 結節性硬化症の遺伝子治療 |
| PCT/US2018/033247 WO2018213618A1 (en) | 2017-05-17 | 2018-05-17 | Gene therapy for tuberous sclerosis |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019558745A Division JP7235676B2 (ja) | 2017-05-17 | 2018-05-17 | 結節性硬化症の遺伝子治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023065516A JP2023065516A (ja) | 2023-05-12 |
| JP2023065516A5 true JP2023065516A5 (https=) | 2023-10-23 |
| JP7725514B2 JP7725514B2 (ja) | 2025-08-19 |
Family
ID=64274693
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019558745A Active JP7235676B2 (ja) | 2017-05-17 | 2018-05-17 | 結節性硬化症の遺伝子治療 |
| JP2023026870A Active JP7725514B2 (ja) | 2017-05-17 | 2023-02-24 | 結節性硬化症の遺伝子治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019558745A Active JP7235676B2 (ja) | 2017-05-17 | 2018-05-17 | 結節性硬化症の遺伝子治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11958887B2 (https=) |
| EP (2) | EP3624856B1 (https=) |
| JP (2) | JP7235676B2 (https=) |
| CA (1) | CA3061656A1 (https=) |
| ES (1) | ES2978297T3 (https=) |
| WO (1) | WO2018213618A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3624856B1 (en) * | 2017-05-17 | 2024-04-03 | The General Hospital Corporation | Gene therapy for tuberous sclerosis |
| CN117715928A (zh) * | 2021-06-14 | 2024-03-15 | 桥生物基因疗法研究有限责任公司 | 用于结节性硬化的基因疗法 |
| AU2024272186A1 (en) * | 2023-05-17 | 2025-11-20 | Ohio State Innovation Foundation | Protein engineering micro-tuberin gene therapy candidates for tuberous sclerosis complex type 2 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| US6884419B1 (en) * | 1996-12-23 | 2005-04-26 | Kyowa Hakko Kogyo, Co., Ltd. | hG-CSF fusion polypeptide having c-mpl activity, DNA coding for same and methods of treating anemia using same |
| DK2359869T3 (en) | 2001-12-17 | 2019-04-15 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof |
| EP1546369A4 (en) | 2002-08-12 | 2007-01-17 | Univ Michigan | DIAGNOSIS AND TREATMENT OF DISEASES THROUGH DEFECTS IN THE TUBEROUS SKLEROSEPFAD |
| WO2004058166A2 (en) | 2002-12-23 | 2004-07-15 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
| US20060239966A1 (en) | 2003-10-20 | 2006-10-26 | Tornoee Jens | In vivo gene therapy of parkinson's disease |
| CL2008000707A1 (es) * | 2007-03-13 | 2008-09-22 | Hoffmann La Roche | Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion. |
| US7561973B1 (en) | 2008-07-31 | 2009-07-14 | Dna Twopointo, Inc. | Methods for determining properties that affect an expression property value of polynucleotides in an expression system |
| US7561972B1 (en) | 2008-06-06 | 2009-07-14 | Dna Twopointo, Inc. | Synthetic nucleic acids for expression of encoded proteins |
| US20120252877A1 (en) * | 2009-08-14 | 2012-10-04 | Theramind Research, Llc | Methods and compositions for treatment of tuberous sclerosis complex |
| US9249425B2 (en) | 2011-05-16 | 2016-02-02 | The Trustees Of The University Of Pennslyvania | Proviral plasmids and production of recombinant adeno-associated virus |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| CA2890346A1 (en) | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
| EP3624856B1 (en) | 2017-05-17 | 2024-04-03 | The General Hospital Corporation | Gene therapy for tuberous sclerosis |
-
2018
- 2018-05-17 EP EP18801604.2A patent/EP3624856B1/en active Active
- 2018-05-17 JP JP2019558745A patent/JP7235676B2/ja active Active
- 2018-05-17 EP EP24168056.0A patent/EP4413990A3/en active Pending
- 2018-05-17 US US16/613,907 patent/US11958887B2/en active Active
- 2018-05-17 ES ES18801604T patent/ES2978297T3/es active Active
- 2018-05-17 WO PCT/US2018/033247 patent/WO2018213618A1/en not_active Ceased
- 2018-05-17 CA CA3061656A patent/CA3061656A1/en active Pending
-
2023
- 2023-02-24 JP JP2023026870A patent/JP7725514B2/ja active Active
-
2024
- 2024-03-12 US US18/602,622 patent/US20240343768A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023065516A5 (https=) | ||
| US20220331409A1 (en) | Factor ix gene therapy | |
| US20120093775A1 (en) | Methods and compositions for the treatment of cirrhosis and liver fibrosis | |
| JP2020533959A5 (https=) | ||
| US20040087028A1 (en) | Ecdysone-inducible adeno-associated virus expression vectors | |
| IL299325B2 (en) | Acid-alpha glucosidase variants and uses thereof | |
| JP2019511570A5 (https=) | ||
| JP7524166B2 (ja) | 脳に指向性を有するａａｖ変異体 | |
| JPWO2020106916A5 (https=) | ||
| JP2020519251A5 (https=) | ||
| JPWO2021050614A5 (https=) | ||
| JPWO2021014428A5 (https=) | ||
| FI3177313T3 (fi) | Telomeraasi-käänteistranskriptaasipohjaisia hoitoja sydäninfarktiin liittyvien tilojen hoitamiseksi | |
| JPWO2020232297A5 (https=) | ||
| JPWO2020186150A5 (https=) | ||
| JPWO2022034130A5 (https=) | ||
| JPWO2021195214A5 (https=) | ||
| JPWO2021222168A5 (https=) | ||
| JPWO2021195218A5 (https=) | ||
| JPWO2020237130A5 (https=) | ||
| JP7853952B2 (ja) | Ｇｌｕｔ１発現のためのアデノ随伴ウイルスベクターおよびその使用 | |
| RU2809389C2 (ru) | Мутант aav, обладающий способностью нацеливаться на головной мозг | |
| US11795207B2 (en) | Modified plasma clotting factor VIII and method of use thereof | |
| AU2019277217A1 (en) | AAV polynucleotides, polypeptides and virions | |
| JPWO2022266113A5 (https=) |